205 related articles for article (PubMed ID: 20634194)
21. Progression and treatment of HER2-positive breast cancer.
Davoli A; Hocevar BA; Brown TL
Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
[TBL] [Abstract][Full Text] [Related]
22. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
23. Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus.
Del Bufalo D; Ciuffreda L; Trisciuoglio D; Desideri M; Cognetti F; Zupi G; Milella M
Cancer Res; 2006 Jun; 66(11):5549-54. PubMed ID: 16740688
[TBL] [Abstract][Full Text] [Related]
24. An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.
Guo Y; Mazar AP; Lebrun JJ; Rabbani SA
Cancer Res; 2002 Aug; 62(16):4678-84. PubMed ID: 12183425
[TBL] [Abstract][Full Text] [Related]
25. Targeting Src in breast cancer.
Finn RS
Ann Oncol; 2008 Aug; 19(8):1379-1386. PubMed ID: 18487549
[TBL] [Abstract][Full Text] [Related]
26. Translational evidence on the role of Src kinase and activated Src kinase in invasive breast cancer.
Elsberger B
Crit Rev Oncol Hematol; 2014 Mar; 89(3):343-51. PubMed ID: 24388104
[TBL] [Abstract][Full Text] [Related]
27. Src as a therapeutic target in men with prostate cancer and bone metastases.
Saad F
BJU Int; 2009 Feb; 103(4):434-40. PubMed ID: 19154462
[TBL] [Abstract][Full Text] [Related]
28. Novel agents and future directions for refractory breast cancer.
Burstein HJ
Semin Oncol; 2011 Jun; 38 Suppl 2():S17-24. PubMed ID: 21600381
[TBL] [Abstract][Full Text] [Related]
29. The role of Src in prostate cancer.
Fizazi K
Ann Oncol; 2007 Nov; 18(11):1765-73. PubMed ID: 17426060
[TBL] [Abstract][Full Text] [Related]
30. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
[TBL] [Abstract][Full Text] [Related]
31. Src kinase inhibitors: promising cancer therapeutics?
Creedon H; Brunton VG
Crit Rev Oncog; 2012; 17(2):145-59. PubMed ID: 22471705
[TBL] [Abstract][Full Text] [Related]
32. Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis.
Delle Monache S; Sanità P; Calgani A; Schenone S; Botta L; Angelucci A
Exp Cell Res; 2014 Oct; 328(1):20-31. PubMed ID: 25128812
[TBL] [Abstract][Full Text] [Related]
33. Src: a potential target for the treatment of triple-negative breast cancer.
Tryfonopoulos D; Walsh S; Collins DM; Flanagan L; Quinn C; Corkery B; McDermott EW; Evoy D; Pierce A; O'Donovan N; Crown J; Duffy MJ
Ann Oncol; 2011 Oct; 22(10):2234-40. PubMed ID: 21357651
[TBL] [Abstract][Full Text] [Related]
34. Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors.
Beetham H; Griffith BGC; Murina O; Loftus AEP; Parry DA; Temps C; Culley J; Muir M; Unciti-Broceta A; Sims AH; Byron A; Brunton VG
Cancer Res; 2022 Feb; 82(4):632-647. PubMed ID: 34921014
[TBL] [Abstract][Full Text] [Related]
35. Nonreceptor tyrosine kinases in prostate cancer.
Chang YM; Kung HJ; Evans CP
Neoplasia; 2007 Feb; 9(2):90-100. PubMed ID: 17357254
[TBL] [Abstract][Full Text] [Related]
36. Src inhibitors in breast cancer therapy.
Hiscox S; Nicholson RI
Expert Opin Ther Targets; 2008 Jun; 12(6):757-67. PubMed ID: 18479222
[TBL] [Abstract][Full Text] [Related]
37. SRC: a century of science brought to the clinic.
Aleshin A; Finn RS
Neoplasia; 2010 Aug; 12(8):599-607. PubMed ID: 20689754
[TBL] [Abstract][Full Text] [Related]
38. Pharmacology of Src family kinases and therapeutic implications of their modulators.
Kumar A; Jaggi AS; Singh N
Fundam Clin Pharmacol; 2015 Apr; 29(2):115-30. PubMed ID: 25545125
[TBL] [Abstract][Full Text] [Related]
39. The molecular rationale of Src inhibition in colorectal carcinomas.
Gargalionis AN; Karamouzis MV; Papavassiliou AG
Int J Cancer; 2014 May; 134(9):2019-29. PubMed ID: 23733480
[TBL] [Abstract][Full Text] [Related]
40. SRC as a therapeutic target in breast cancer.
Morgan L; Nicholson RI; Hiscox S
Endocr Metab Immune Disord Drug Targets; 2008 Dec; 8(4):273-8. PubMed ID: 19075780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]